Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): A multicenter randomized trial

摘要: Summary Purpose: The combination of paclitaxel and carboplatin has become a widely used regimen in NSCLC due to phase II reports moderate toxicity, reasonable activity easy out- patient administration. Purpose our present prospective study was evaluate the dose-response relationship paclitaxel. Patients methods: Since July 1996, 198 patients with non-operable measurable disease without pre- vious chemotherapy entered trial. Ninety nine (group A) were randomized receive 175 mg/m 2 three-hour infusion plus dosed an area under concentration-time curve 6 every 3 weeks 99 B) same increased 225 . Eligibility criteria included WHO performance status 0-2, documented inoperable stage IIIA IIIB, IV, no brain metastasis, prior adequate renal hepatic function. both groups well-matched baseline characteristics.